{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:37:14Z","timestamp":1794490634476,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K24CA201543-01"],"award-info":[{"award-number":["K24CA201543-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA70907"],"award-info":[{"award-number":["P50CA70907"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP110708"],"award-info":[{"award-number":["RP110708"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["RO1CA197796"],"award-info":[{"award-number":["RO1CA197796"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA244212-01A1"],"award-info":[{"award-number":["1R01CA244212-01A1"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["2I01BX002559-07"],"award-info":[{"award-number":["2I01BX002559-07"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Inhibition of RTK pathways in cancer triggers an adaptive response that promotes therapeutic resistance. Because the adaptive response is multifaceted, the optimal approach to blunting it remains undetermined. TNF upregulation is a biologically significant response to EGFR inhibition in NSCLC. Here, we compared a specific TNF inhibitor (etanercept) to thalidomide and prednisone, two drugs that block TNF and also other inflammatory pathways. Prednisone is significantly more effective in suppressing EGFR inhibition-induced inflammatory signals. Remarkably, prednisone induces a shutdown of bypass RTK signaling and inhibits key resistance signals such as STAT3, YAP and TNF-NF-\u03baB. Combined with EGFR inhibition, prednisone is significantly superior to etanercept or thalidomide in durably suppressing tumor growth in multiple mouse models, indicating that a broad suppression of adaptive signals is more effective than blocking a single component. We identify prednisone as a drug that can effectively inhibit adaptive resistance with acceptable toxicity in NSCLC and other cancers.<\/jats:p>","DOI":"10.1038\/s41467-021-27276-7","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T11:04:42Z","timestamp":1638356682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids"],"prefix":"10.1038","volume":"12","author":[{"given":"Ke","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Beckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7812-6741","authenticated-orcid":false,"given":"David E.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7776-0767","authenticated-orcid":false,"given":"John D.","family":"Minna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7057-9845","authenticated-orcid":false,"given":"Sandeep","family":"Burma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6428-1698","authenticated-orcid":false,"given":"Dawen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4149-2529","authenticated-orcid":false,"given":"Esra A.","family":"Akbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-9028","authenticated-orcid":false,"given":"Amyn A.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"27276_CR1","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/annonc\/mdi408","volume":"16","author":"T Dutu","year":"2005","unstructured":"Dutu, T. et al. Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Ann. Oncol. 16, 1906\u20131914 (2005).","journal-title":"Ann. Oncol."},{"key":"27276_CR2","first-page":"2379","volume":"53","author":"V Rusch","year":"1993","unstructured":"Rusch, V. et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53, 2379\u20132385 (1993).","journal-title":"Cancer Res."},{"key":"27276_CR3","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/nm.3388","volume":"19","author":"CR Chong","year":"2013","unstructured":"Chong, C. R. & Janne, P. A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19, 1389\u20131400 (2013).","journal-title":"Nat. Med."},{"key":"27276_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0793-1","volume":"17","author":"Q Liu","year":"2018","unstructured":"Liu, Q. et al. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol. Cancer 17, 53 (2018).","journal-title":"Mol. Cancer"},{"key":"27276_CR5","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129\u20132139 (2004).","journal-title":"N. Engl. J. Med."},{"key":"27276_CR6","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497\u20131500 (2004).","journal-title":"Science"},{"key":"27276_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169\u2013181 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"27276_CR8","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1002\/cncr.22903","volume":"110","author":"M Volante","year":"2007","unstructured":"Volante, M. et al. Epidermal growth factor ligand\/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer. Cancer 110, 1321\u20131328 (2007).","journal-title":"Cancer"},{"key":"27276_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0169-5002(00)00116-1","volume":"29","author":"ET Hsieh","year":"2000","unstructured":"Hsieh, E. T., Shepherd, F. A. & Tsao, M. S. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma. Lung Cancer 29, 151\u2013157 (2000).","journal-title":"Lung Cancer"},{"key":"27276_CR10","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1158\/0008-5472.CAN-15-0989","volume":"75","author":"G Guo","year":"2015","unstructured":"Guo, G. et al. Ligand-Independent EGFR Signaling. Cancer Res. 75, 3436\u20133441 (2015).","journal-title":"Cancer Res."},{"key":"27276_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6811","volume":"5","author":"S Chakraborty","year":"2014","unstructured":"Chakraborty, S. et al. Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks. Nat. Commun. 5, 5811 (2014).","journal-title":"Nat. Commun."},{"key":"27276_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cell.2012.12.032","volume":"152","author":"NF Endres","year":"2013","unstructured":"Endres, N. F. et al. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 152, 543\u2013556 (2013).","journal-title":"Cell"},{"key":"27276_CR13","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nm.4091","volume":"22","author":"TG Bivona","year":"2016","unstructured":"Bivona, T. G. & Doebele, R. C. A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat. Med. 22, 472\u2013478 (2016).","journal-title":"Nat. Med."},{"key":"27276_CR14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc.2017.84","volume":"17","author":"J Rotow","year":"2017","unstructured":"Rotow, J. & Bivona, T. G. Understanding and targeting resistance mechanisms in NSCLC. Nat. Rev. Cancer 17, 637\u2013658 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"27276_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee, H. J. et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26, 207\u2013221 (2014).","journal-title":"Cancer Cell"},{"key":"27276_CR16","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu, H. A. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res 19, 2240\u20132247 (2013).","journal-title":"Clin. Cancer Res"},{"key":"27276_CR17","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039\u20131043 (2007).","journal-title":"Science"},{"key":"27276_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","volume":"19","author":"S Chandarlapaty","year":"2011","unstructured":"Chandarlapaty, S. et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58\u201371 (2011).","journal-title":"Cancer Cell"},{"key":"27276_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100\u2013103 (2012).","journal-title":"Nature"},{"key":"27276_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","volume":"149","author":"JS Duncan","year":"2012","unstructured":"Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307\u2013321 (2012).","journal-title":"Cell"},{"key":"27276_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1158\/2159-8290.CD-12-0502","volume":"3","author":"D Akhavan","year":"2013","unstructured":"Akhavan, D. et al. De-repression of PDGFRbeta transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 3, 534\u2013547 (2013).","journal-title":"Cancer Discov."},{"key":"27276_CR22","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1158\/0008-5472.CAN-15-1248","volume":"75","author":"KC Wood","year":"2015","unstructured":"Wood, K. C. Mapping the pathways of resistance to targeted therapies. Cancer Res. 75, 4247\u20134251 (2015).","journal-title":"Cancer Res."},{"key":"27276_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.tibs.2014.08.010","volume":"39","author":"C Sun","year":"2014","unstructured":"Sun, C. & Bernards, R. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem. Sci. 39, 465\u2013474 (2014).","journal-title":"Trends Biochem. Sci."},{"key":"27276_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.celrep.2015.03.012","volume":"11","author":"CM Blakely","year":"2015","unstructured":"Blakely, C. M. et al. NF-kappaB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 11, 98\u2013110 (2015).","journal-title":"Cell Rep."},{"key":"27276_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1158\/2159-8290.CD-17-0461","volume":"8","author":"M Rusan","year":"2018","unstructured":"Rusan, M. et al. Suppression of adaptive responses to targeted cancer therapy by transcriptional repression. Cancer Discov. 8, 59\u201373 (2018).","journal-title":"Cancer Discov."},{"key":"27276_CR26","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1172\/JCI96148","volume":"128","author":"K Gong","year":"2018","unstructured":"Gong, K. et al. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J. Clin. Invest. 128, 2500\u20132518 (2018).","journal-title":"J. Clin. Invest."},{"key":"27276_CR27","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s43018-020-0048-0","volume":"1","author":"K Gong","year":"2020","unstructured":"Gong, K. et al. EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nat. Cancer 1, 394\u2013409 (2020).","journal-title":"Nat. Cancer"},{"key":"27276_CR28","doi-asserted-by":"publisher","first-page":"797","DOI":"10.15252\/msb.20145877","volume":"11","author":"M Fallahi-Sichani","year":"2015","unstructured":"Fallahi-Sichani, M. et al. Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK\/c-Jun pathway in adaptive resistance to drug-induced apoptosis. Mol. Syst. Biol. 11, 797 (2015).","journal-title":"Mol. Syst. Biol."},{"key":"27276_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1042\/cs0940557","volume":"94","author":"PJ Barnes","year":"1998","unstructured":"Barnes, P. J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. 94, 557\u2013572 (1998).","journal-title":"Clin. Sci."},{"key":"27276_CR30","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/nn.4584","volume":"20","author":"G Guo","year":"2017","unstructured":"Guo, G. et al. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Nat. Neurosci. 20, 1074\u20131084 (2017).","journal-title":"Nat. Neurosci."},{"key":"27276_CR31","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/neuonc\/noz127","volume":"21","author":"G Guo","year":"2019","unstructured":"Guo, G. et al. Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. Neuro Oncol. 21, 1529\u20131539 (2019).","journal-title":"Neuro Oncol."},{"key":"27276_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neo.2020.12.006","volume":"23","author":"K Gong","year":"2021","unstructured":"Gong, K. et al. Tumor necrosis factor in lung cancer: complex roles in biology and resistance to treatment. Neoplasia 23, 189\u2013196 (2021).","journal-title":"Neoplasia"},{"key":"27276_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain, D. W. & Cidlowski, J. A. Immune regulation by glucocorticoids. Nat. Rev. Immunol. 17, 233\u2013247 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"27276_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1128\/MMBR.00064-15","volume":"80","author":"I Petta","year":"2016","unstructured":"Petta, I. et al. The interactome of the glucocorticoid receptor and its influence on the actions of glucocorticoids in combatting inflammatory and infectious diseases. Microbiol. Mol. Biol. Rev. 80, 495\u2013522 (2016).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"27276_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho, A. E. & Chapman, K. E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell Endocrinol. 335, 2\u201313 (2011).","journal-title":"Mol. Cell Endocrinol."},{"key":"27276_CR36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","volume":"25","author":"LM Sedger","year":"2014","unstructured":"Sedger, L. M. & McDermott, M. F. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants\u2014past, present and future. Cytokine Growth Factor Rev. 25, 453\u2013472 (2014).","journal-title":"Cytokine Growth Factor Rev."},{"key":"27276_CR37","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","volume":"177","author":"AL Moreira","year":"1993","unstructured":"Moreira, A. L. et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med 177, 1675\u20131680 (1993).","journal-title":"J. Exp. Med"},{"key":"27276_CR38","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1158\/2159-8290.CD-12-0103","volume":"2","author":"D Ercan","year":"2012","unstructured":"Ercan, D. et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2, 934\u2013947 (2012).","journal-title":"Cancer Discov."},{"key":"27276_CR39","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.270.5234.286","volume":"270","author":"N Auphan","year":"1995","unstructured":"Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A. & Karin, M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270, 286\u2013290 (1995).","journal-title":"Science"},{"key":"27276_CR40","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1158\/2159-8290.CD-12-0237","volume":"2","author":"F Harbinski","year":"2012","unstructured":"Harbinski, F. et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov. 2, 948\u2013959 (2012).","journal-title":"Cancer Discov."},{"key":"27276_CR41","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nature11249","volume":"487","author":"TR Wilson","year":"2012","unstructured":"Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505\u2013509 (2012).","journal-title":"Nature"},{"key":"27276_CR42","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbrc.2016.04.089","volume":"474","author":"JE Lee","year":"2016","unstructured":"Lee, J. E. et al. Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. Biochem. Biophys. Res. Commun. 474, 154\u2013160 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"27276_CR43","doi-asserted-by":"crossref","unstructured":"Chaib, I. et al. Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC. J. Natl Cancer Inst. 109, djx014 (2017).","DOI":"10.1093\/jnci\/djx014"},{"key":"27276_CR44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","volume":"37","author":"KJ Kurppa","year":"2020","unstructured":"Kurppa, K. J. et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell 37, 104\u2013122.e112 (2020).","journal-title":"Cancer Cell"},{"key":"27276_CR45","doi-asserted-by":"crossref","unstructured":"Nilsson, M. B. et al. A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci. Transl Med. 12, eaaz4589 (2020).","DOI":"10.1126\/scitranslmed.aaz4589"},{"key":"27276_CR46","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/0008-5472.CAN-10-2668","volume":"71","author":"W Fan","year":"2011","unstructured":"Fan, W. et al. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res. 71, 4494\u20134505 (2011).","journal-title":"Cancer Res."},{"key":"27276_CR47","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1043-2760(99)00186-1","volume":"10","author":"JC Webster","year":"1999","unstructured":"Webster, J. C. & Cidlowski, J. A. Mechanisms of glucocorticoid-receptor-mediated repression of gene expression. Trends Endocrinol. Metab. 10, 396\u2013402 (1999).","journal-title":"Trends Endocrinol. Metab."},{"key":"27276_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27\u201331 (2016).","journal-title":"J. Basic Clin. Pharm."},{"key":"27276_CR49","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1101\/gad.1417406","volume":"20","author":"K Politi","year":"2006","unstructured":"Politi, K. et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20, 1496\u20131510 (2006).","journal-title":"Genes Dev."},{"key":"27276_CR50","doi-asserted-by":"publisher","first-page":"464","DOI":"10.21037\/tlcr.2018.06.04","volume":"7","author":"EA Akbay","year":"2018","unstructured":"Akbay, E. A. & Kim, J. Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl. Lung Cancer Res 7, 464\u2013486 (2018).","journal-title":"Transl. Lung Cancer Res"},{"key":"27276_CR51","doi-asserted-by":"crossref","unstructured":"Kruspig, B. et al. The ERBB network facilitates KRAS-driven lung tumorigenesis. Sci. Transl Med. 10, eaao2565 (2018).","DOI":"10.1126\/scitranslmed.aao2565"},{"key":"27276_CR52","doi-asserted-by":"crossref","unstructured":"Moll, H. P. et al. Afatinib restrains K-RAS-driven lung tumorigenesis. Sci. Transl Med. 10, eaao2301 (2018).","DOI":"10.1126\/scitranslmed.aao2301"},{"key":"27276_CR53","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1200\/JCO.2012.43.3912","volume":"31","author":"K Ohashi","year":"2013","unstructured":"Ohashi, K., Maruvka, Y. E., Michor, F. & Pao, W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J. Clin. Oncol. 31, 1070\u20131080 (2013).","journal-title":"J. Clin. Oncol."},{"key":"27276_CR54","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1172\/JCI31871","volume":"117","author":"SP Gao","year":"2007","unstructured":"Gao, S. P. et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117, 3846\u20133856 (2007).","journal-title":"J. Clin. Invest."},{"key":"27276_CR55","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMe0905763","volume":"361","author":"AF Gazdar","year":"2009","unstructured":"Gazdar, A. F. Personalized medicine and inhibition of EGFR signaling in lung cancer. N. Engl. J. Med. 361, 1018\u20131020 (2009).","journal-title":"N. Engl. J. Med."},{"key":"27276_CR56","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/S0140-6736(15)01125-3","volume":"387","author":"R Rosell","year":"2016","unstructured":"Rosell, R. & Karachaliou, N. Large-scale screening for somatic mutations in lung cancer. Lancet 387, 1354\u20131356 (2016).","journal-title":"Lancet"},{"key":"27276_CR57","doi-asserted-by":"crossref","unstructured":"Hsu, P. C., Jablons, D. M., Yang, C. T. & You, L. Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC). Int. J. Mol. Sci. 20, 3821 (2019).","DOI":"10.3390\/ijms20153821"},{"key":"27276_CR58","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1080\/15384101.2015.1032644","volume":"14","author":"KT Flaherty","year":"2015","unstructured":"Flaherty, K. T., Wargo, J. A. & Bivona, T. G. YAP in MAPK pathway targeted therapy resistance. Cell Cycle 14, 1765\u20131766 (2015).","journal-title":"Cell Cycle"},{"key":"27276_CR59","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.18632\/oncotarget.2974","volume":"6","author":"B You","year":"2015","unstructured":"You, B. et al. Inhibition of ERK1\/2 down-regulates the Hippo\/YAP signaling pathway in human NSCLC cells. Oncotarget 6, 4357\u20134368 (2015).","journal-title":"Oncotarget"},{"key":"27276_CR60","doi-asserted-by":"publisher","first-page":"51922","DOI":"10.18632\/oncotarget.10458","volume":"7","author":"PC Hsu","year":"2016","unstructured":"Hsu, P. C. et al. YAP promotes erlotinib resistance in human non-small cell lung cancer cells. Oncotarget 7, 51922\u201351933 (2016).","journal-title":"Oncotarget"},{"key":"27276_CR61","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3747\/co.v18i3.877","volume":"18","author":"V Hirsh","year":"2011","unstructured":"Hirsh, V. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr. Oncol. 18, 126\u2013138 (2011).","journal-title":"Curr. Oncol."},{"key":"27276_CR62","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.celrep.2013.07.025","volume":"4","author":"VT Puliyappadamba","year":"2013","unstructured":"Puliyappadamba, V. T. et al. Opposing effect of EGFRWT on EGFRvIII-mediated NF-kappaB activation with RIP1 as a cell death switch. Cell Rep. 4, 764\u2013775 (2013).","journal-title":"Cell Rep."},{"key":"27276_CR63","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"27276_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"27276_CR65","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"27276_CR66","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"27276_CR67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-020-00292-x","volume":"22","author":"E Armingol","year":"2021","unstructured":"Armingol, E., Officer, A., Harismendy, O. & Lewis, N. E. Deciphering cell-cell interactions and communication from gene expression. Nat. Rev. Genet. 22, 71\u201388 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"27276_CR68","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1093\/nar\/gkaa183","volume":"48","author":"S Cabello-Aguilar","year":"2020","unstructured":"Cabello-Aguilar, S. et al. SingleCellSignalR: inference of intercellular networks from single-cell transcriptomics. Nucleic Acids Res. 48, e55 (2020).","journal-title":"Nucleic Acids Res."},{"key":"27276_CR69","doi-asserted-by":"crossref","unstructured":"Shao, X. et al. CellTalkDB: a manually curated database of ligand-receptor interactions in humans and mice. Brief Bioinform. 22, bbaa269 (2021).","DOI":"10.1093\/bib\/bbaa269"},{"key":"27276_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18873-z","volume":"11","author":"R Hou","year":"2020","unstructured":"Hou, R., Denisenko, E., Ong, H. T., Ramilowski, J. A. & Forrest, A. R. R. Predicting cell-to-cell communication networks using NATMI. Nat. Commun. 11, 5011 (2020).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27276-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27276-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27276-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T12:10:48Z","timestamp":1675944648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27276-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["27276"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-27276-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]},"assertion":[{"value":"23 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Department of Veteran\u2019s Affairs has filed a patent for the combined use of EGFR inhibitors plus prednisone in lung cancer with Amyn Habib as the inventor. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7014"}}